Journal
CELL METABOLISM
Volume 29, Issue 2, Pages 246-253Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2019.01.004
Keywords
-
Categories
Funding
- National Institutes of Health [R01DK067158, P01AG051459]
- Robert A. Welch Foundation [I-1558, I-1275]
- Howard Hughes Medical Institute
Ask authors/readers for more resources
It has been more than a dozen years since FGF21 burst on the metabolism field in a paper showing that its pharmacologic administration caused weight loss and improved insulin sensitivity and lipoprotein profiles in obese rodents. Since then, FGF21 analogs have advanced all the way to clinical trials, and much progress has been made in understanding FGF21's pharmacology and physiology. In this Perspective, we highlight some of the interesting themes that have emerged from this first dozen years of FGF21 research, including its roles in autocrine/paracrine and endocrine responses to metabolic stress.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available